Form 4: Cyclo Therapeutics Director Receives Stock Grant in Lieu of Cash Compensation

A Cyclo Therapeutics director, C.E. Rick Strattan, received 63,608 shares of common stock in lieu of cash compensation for the third quarter of 2024.

Summary

• C.E. Rick Strattan, a director at Cyclo Therapeutics, received 63,608 shares of common stock.
• This stock grant was in place of cash compensation for the third quarter of 2024.
• The number of shares was calculated based on a price of $0.66 per share, which was the closing price on November 14, 2024.
• Following this transaction, Mr. Strattan beneficially owns 369,103 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed neutrally to slightly positive as it aligns director interests with shareholders.

Positives

• The director's decision to take stock instead of cash may indicate confidence in the company's future performance.

Industry Context

This is a standard practice for compensating non-employee directors, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Many companies use stock grants as part of their director compensation packages.
• The practice of using the closing price on a specific date to calculate the number of shares is common.
• This type of compensation is often used to align the interests of directors with the long-term success of the company, similar to practices at companies like Amgen and Biogen.

Stakeholder Impact

• The stock grant increases the director's stake in the company, aligning his interests with those of shareholders.

Key Dates

Keywords

Cyclo Therapeutics, Director Compensation, Stock Grant, Form 4, Insider Trading, Equity Compensation